1231 ECP Cardior
BioCentury & Getty Images

Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

Emerging Company Profile: Cardior is betting on RNA therapies that aim to help dysfunctional hearts pump more efficiently.

Hannover Medical School spinout Cardior is developing non-coding RNA therapies that aim to help dysfunctional hearts pump more efficiently.

By Danielle Golovin, Staff Writer
Dec 31, 2020 | 9:26 PM GMT
Editor's note: This profile has been updated to correct the name of the heart failure marker NT-proBNP and the result for the Phase Ib trial's placebo group. Updated on Jan 4, 2021 at 2:05 PM GMT

Cardior plans to build on early clinical data for its antisense oligonucleotide in heart failure patients by moving the RNA therapy into niche

Read the full 799 word article

How to gain access

Continue reading with a
two-week free trial.